{
  "source": "PA-Notification-Iwilfin.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1433-2\nProgram Prior Authorization/Notification\nMedication Iwilfin™ (eflornithine)\nP&T Approval Date 2/2024, 2/2025\nEffective Date 5/1/2025\n1. Background:\nIwilfin (eflornithine) is an ornithine decarboxylase inhibitor indicated to reduce the risk of relapse\nin adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at\nleast a partial response to prior multiagent, multimodality therapy including anti-GD2\nimmunotherapy.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Iwilfin will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. High-Risk Neuroblastoma (HRNB)\n1. Initial Authorization\na. Iwilfin will be approved based on all of the following criteria:\n(1) Diagnosis of high-risk neuroblastoma (HRNB)\n-AND-\n(2) Patient has shown at least a partial response to prior multiagent, multimodality\ntherapy\n-AND-\n(3) Prior therapy included anti-GD2 immunotherapy (e.g., Danyelza (naxitamab-\ngqgk), Unituxin (dinutuximab))\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Iwilfin will be approved based on the following criterion:\n© 2025 UnitedHealthcare Services Inc.\n1\n(1) Patient does not show evidence of progressive disease while on Iwilfin therapy\nAuthorization will be issued for 12 months.\nC. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category\nof Evidence and Consensus of 1, 2A, or 2B.\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approv",
    "coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Iwilfin [package insert]. USWM, LLC.: Louisville, KY; December 2023.\nProgram Prior Authorization/Notification – Iwilfin™ (eflornithine)\nChange Control\n2/2024 New program.\n2/2025 Annual review. No changes to clinical criteria.\n© 2025 UnitedHealthcare Services Inc.\n2"
  ]
}